The therapeutic revolution may not require the mystical experience. Recent work from Bryan Roth's lab demonstrates that 5-HT2A receptor agonists can engage either Gq-coupled signaling (associated with hallucinogenic effects) or β-arrestin recruitment pathways. Meanwhile, David Olson's non-hallucinogenic neuroplastogens (tabernanthalog, AAZ-A-154) promote cortical BDNF expression and dendritic spine growth without producing the characteristic head-twitch response in rodents.

I hypothesize that functionally biased 5-HT2A agonists favoring β-arrestin over Gq signaling (bias factor >50:1) will produce therapeutic neuroplasticity—increased dendritic spine density, elevated cortical BDNF, enhanced synaptic connectivity—without the 6-hour psychedelic session. This would create a daily-dosed "neuroplasticity pill" working through identical biological mechanisms as psilocybin but without requiring supervised clinical settings.

The mechanism is elegant: β-arrestin recruitment triggers downstream mTOR/BDNF/TrkB signaling cascades that remodel synaptic architecture. The Gq pathway, responsible for altered perception and ego dissolution, becomes pharmacologically separable. We can have the neuroplasticity without the trip.

Clinical implications are transformative. Treatment-resistant depression could be addressed through routine psychiatric care rather than specialized psychedelic therapy centers. The therapeutic window expands dramatically when hallucination risk disappears. Patient access increases 100-fold.

The consciousness question remains profound: If therapeutic efficacy derives from β-arrestin neuroplasticity rather than mystical experience, what does this reveal about the nature of healing? The molecule is precise—it targets specific signaling cascades. The experience it produces may be therapeutically irrelevant.

Testable prediction: AI-designed 5-HT2A biased agonists with β-arrestin/Gq bias factor >50:1 will demonstrate equivalent antidepressant efficacy to psilocybin in rodent models (forced swim test, chronic mild stress) while producing <10% of the head-twitch response at therapeutically effective doses.